Kinapse is pleased to announce its support of Talentmark’s 40th Anniversary celebrations at a ‘Futureceuticals’ event being held today at the Royal College of Surgeons in London.
Andy Black, Kinapse Chief Executive Officer, and Fellow of the Royal College of Surgeons, will be attending the evening and delivering a presentation on “Ideas about the future of the Innovative Pharmaceutical Industry”.
Andy commented: “I am delighted to return to my alma mater and to support our friends at Talentmark. I am looking forward to some lively discussion, and hope to share some optimism about the future of our industry, which is so important to all of us here in the UK”.

Kinapse Ltd.

About Kinapse

‘Collaborating with our clients to innovate for exceptional results’ Kinapse provides business consulting and outsourcing to life sciences organisations. Its clients include many of the world’s leading pharmaceutical companies, leading biotechnology, specialty pharmaceutical and medical devices companies, government organisations and industry service providers.
Headquartered in the UK, Kinapse has offices in London, Philadelphia and New Delhi with partners based in the Americas, Europe and Asia-Pacific. Kinapse blends expertise from its multiple locations to deliver services for clients at highest quality and differentiated value. The novel features of its operating model include:
– exclusive focus on life sciences;
– blended onshore-offshore teams, tailored to client requirements;
– ex-industry-Consulting Partners who bring deep experience and expertise in specific
functional and technical areas;
– niche Service Partners with distinctive, complementary services.

Contact:
Andy Black,
Chief Executive Officer
P: +44 (0) 20 8946 7600
Web site: www.kinapse.com
General enquiries: info@kinapse.com

Kinapse announced today that it has been selected through a European open procurement procedure to provide data management services to the European Medicines Agency (EMA). The estimated contract value is € 6,500,000.

The scope of the agreed framework contract covers detection and management of duplicate Individual Case Safety Reports (ICSRs), manual recoding of medicinal product information contained in the ICSRs, data validation and cleaning of medicinal product information in the EVMPD, quality control of ICSRs and translation of case narratives in ICSRs.

Andy Black, Kinapse Chief Executive Officer commented “We are delighted that the EMA has entrusted Kinapse to successfully deliver this critical priority. We will be making every effort, in close collaboration with the EMA, to enhance the quality of the data residing within EudraVigilance over the next four years. This contract enables Kinapse to play an important role in supporting the enhancement of pharmacovigilance across the European Union and globally, together with our delivery partners the International Institute for the Safety of Medicines (ii4sm), QSI and RWS Translation Services.”

“We are very pleased that we have been chosen to provide pharmacovigilance expert consulting and quality assurance services to EMA in collaboration with Kinapse” said Dr. Roland Haag, CEO ii4sm. “This important contract is a recognition for ii4sm as a comprehensive provider of specialized safety services for the life sciences sector.’’

Kinapse Ltd.

About Kinapse

Kinapse provides consulting and outsourcing services to the global life sciences industries.
Our clients include many of the world’s leading pharmaceutical, biotechnology, medical device and specialty pharmaceutical companies, government organisations and life sciences service providers.

Kinapse specialises in addressing the challenges of life sciences. We understand the complex issues faced throughout the life sciences value chain and offer innovative insights, advice and service delivery to our clients.

Contact:
louiza.senaini@kinapse.com, info@kinapse.com, +44 (0)208 946 7600

The Board of Directors of Kinapse Ltd. is delighted to announce that Chris Brinsmead has agreed to become a Non-Executive Director of Kinapse. Chris has had a long and distinguished career in the pharmaceutical industry, notably with Astra Zeneca where he was the President of their UK business. He has also recently served as President of the Association of the British Pharmaceutical Industry (ABPI).

Nick Edwards, Chairman of Kinapse Ltd., said, “I am delighted that Chris has agreed to join the Board of Kinapse. He will bring an extremely valuable perspective to our leadership of the business. We all look forward to working with him as Kinapse pursues its aggressive growth agenda.”

Kinapse Ltd.

About Kinapse

Kinapse provides consulting and outsourcing services to the global life sciences industries.

Our clients include many of the world’s leading pharmaceutical, biotechnology, medical device and specialty pharmaceutical companies, government organisations and life sciences service providers.

Kinapse specialises in addressing the challenges of life sciences. We understand the complex issues faced throughout the life sciences value chain and offer innovative insights, advice and service delivery to our clients.

Contact:
info@kinapse.com, +44 (0)208 946 7600

The Board of Directors of Kinapse Ltd. today announced that Andy Black has been appointed to succeed Shalabh Kumar as Chief Executive Officer, effective immediately.

Andy Black said “I am pleased and honoured to once again take on the Chief Executive role. My first priorities will be to ensure that Kinapse’s clients receive outstanding service, and that our people have every opportunity to fulfill their enormous potential as we continue to expand our services and operations.”

Kinapse Ltd.

About Kinapse

Kinapse provides consulting and outsourcing services to the global life sciences industries.

Our clients include many of the world’s leading pharmaceutical, biotechnology, medical device and specialty pharmaceutical companies, government organisations and life sciences service providers.

Kinapse specialises in addressing the challenges of life sciences. We understand the complex issues faced throughout the life sciences value chain and offer innovative insights, advice and service delivery to our clients.

Contact:
info@kinapse.com, +44 (0)208 946 7600

The Board of Directors of Kinapse Ltd. today announced that Co-founder Shalabh Kumar has stepped down as Chief Executive Officer, effective immediately. He will continue as a Shareholder and as a Non-executive Director on the Board of Kinapse Ltd.

Nick Edwards, Chairman of Kinapse Ltd., said, “I would like to thank Shalabh for his contributions as a Co-founder, Chief Operating Officer and then Chief Executive of Kinapse. He has played a significant role in building Kinapse as a business and as an organisation in the last five years. We look forward to his continued support to the growth of the business as a member of the Board and wish him well.”

Shalabh Kumar said, “It has been an exciting and demanding five years of building Kinapse and I am thankful to all the people, clients, employees and others, who have supported us in the journey. I believe Kinapse has a great future in its chosen lines of business but have had differences with the Board over the strategic focus of the business and have hence agreed to step away from an executive role in the company.”

Kinapse Ltd.

About Kinapse

Kinapse provides consulting and outsourcing services to the global life sciences industries.

Our clients include many of the world’s leading pharmaceutical, biotechnology, medical device and specialty pharmaceutical companies, government organisations and life sciences service providers.

Kinapse specialises in addressing the challenges of life sciences. We understand the complex issues faced throughout the life sciences value chain and offer innovative insights, advice and service delivery to our clients.

Contact:

info@kinapse.com, +44 (0)208 946 7600

London, UK (September 4th, 2009)

Kinapse are pleased to announce their role as collaborative partner and sponsor of the 5th Annual Project & Portfolio Management in the Pharmaceutical Industry Conference in Vienna, Austria on the 17th and 18th September 2009. This event will bring together experts from the pharmaceutical industry to discuss best practices in executing effective project & portfolio management.

Global Head of Client Services for Kinapse, Andy Black, will be attending the conference and delivering a presentation on “Effective Portfolio and Project Management”, covering the challenges facing pharmaceutical and biotechnology executives when managing their portfolio, projects and resources and, based on recent experiences, the implementation of successful solutions.

Kinapse have successfully delivered a wide range of engagements across the Project & Portfolio Management spectrum. Its projects have covered data extraction, cleaning, analysis and reporting; capability assessments and supporting organisations tackling discrete PPRM problems and building best-in-class capabilities.

Kinapse continues to focus exclusively on the life science industry and our innovative and collaborative work style remains as important to us and our clients as ever.

 For more information do not hesitate to contact us.

Although there is no simple answer, a combination of solutions, such as working with patient groups and using new technology, could increase compliance rates.  A change in business model away from acquisition focused to retention based marketing is also needed. 

Even a 10% increase in compliance would result in billions more revenues – revenues that an industry plagued with patent expires could do with.

 For more information contact us .